Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
14.40
-0.03 (-0.21%)
May 7, 2026, 12:30 PM EDT - Market open
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $70.87M in the quarter ending March 31, 2026, with 35.14% growth. This brings the company's revenue in the last twelve months to $295.41M, up 55.87% year-over-year. In the year 2025, Adaptive Biotechnologies had annual revenue of $276.98M with 54.77% growth.
Revenue (ttm)
$295.41M
Revenue Growth
+55.87%
P/S Ratio
7.82
Revenue / Employee
$473,409
Employees
624
Market Cap
2.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.98M | 98.02M | 54.77% |
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.04B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
ADPT News
- 8 hours ago - Adaptive Biotechnologies price target lowered to $19 from $21 at JPMorgan - TheFly
- 10 hours ago - Adaptive Biotechnologies price target raised to $21 from $19 at TD Cowen - TheFly
- 1 day ago - Adaptive Biotechnologies Earnings Call Transcript: Q1 2026 - Transcripts
- 1 day ago - Adaptive Biotechnologies Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 21 days ago - Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 3 months ago - Adaptive Biotechnologies price target raised to $21 from $20 at TD Cowen - TheFly
- 3 months ago - Adaptive Biotechnologies price target raised to $22 from $21 at BTIG - TheFly